Hoover Nancy G, Heard Michael, Reid Christopher, Wagoner Scott, Rogers Kristine, Foland Jason, Paden Matthew L, Fortenberry James D
Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA.
Intensive Care Med. 2008 Dec;34(12):2241-7. doi: 10.1007/s00134-008-1200-y. Epub 2008 Jul 15.
BACKGROUND/PURPOSE: Children receiving extracorporeal membrane oxygenation (ECMO) for respiratory failure can have significant fluid overload and renal insufficiency. Addition of inline continuous venovenous hemofiltration (CVVH) could provide additional benefits in fluid management compared to use of standard medical therapies with ECMO.
Patients with pediatric respiratory failure receiving ECMO with CVVH were case-matched to similar patients receiving ECMO without CVVH to compare fluid balance, medication use, and clinical outcomes.
Twenty-six of eighty-six patients with pediatric respiratory failure on ECMO (30%) received CVVH for >24 h (median 7.5 days on CVVH). Survival was not significantly different between patients receiving CVVH and those who did not receive CVVH (P = 0.51). For ECMO survivors receiving CVVH, overall fluid balance was less than that in non-CVVH survivors (median 25.1 ml kg(-1) day(-1); range -40.2 to 71.2 vs. 40.2, 1.1 to 134.9; P = 0.028). Time to desired caloric intake was faster in patients receiving CVVH (1 day, 1-5) than in patients who did not receive CVVH (5 days; 1-11; P < 0.001). Patients receiving CVVH-ECMO also received less furosemide (0.67 vs. 2.11 mg kg(-1) day(-1); P = 0.009).
Use of CVVH in ECMO was associated with improved fluid balance and caloric intake and less diuretics than in case-matched ECMO controls.
背景/目的:接受体外膜肺氧合(ECMO)治疗呼吸衰竭的儿童可能会出现明显的液体超负荷和肾功能不全。与使用ECMO的标准药物治疗相比,增加在线持续静脉-静脉血液滤过(CVVH)在液体管理方面可能会带来更多益处。
将接受ECMO联合CVVH治疗的小儿呼吸衰竭患者与接受ECMO但未接受CVVH的类似患者进行病例匹配,以比较液体平衡、药物使用和临床结局。
86例接受ECMO治疗的小儿呼吸衰竭患者中有26例(30%)接受CVVH治疗超过24小时(CVVH治疗的中位时间为7.5天)。接受CVVH治疗的患者与未接受CVVH治疗的患者的生存率无显著差异(P = 0.51)。对于接受CVVH治疗的ECMO幸存者,总体液体平衡低于未接受CVVH治疗的幸存者(中位值为25.1 ml·kg⁻¹·天⁻¹;范围为-40.2至71.2,而未接受CVVH治疗的幸存者为40.2,范围为1.1至134.9;P = 0.028)。接受CVVH治疗的患者达到期望热量摄入的时间比未接受CVVH治疗的患者更快(1天,范围为1至5天)(未接受CVVH治疗的患者为5天;范围为1至11天;P < 0.001)。接受CVVH-ECMO治疗的患者使用的速尿也更少(0.67 vs. 2.11 mg·kg⁻¹·天⁻¹;P = 0.009)。
与病例匹配的ECMO对照组相比,在ECMO中使用CVVH与改善液体平衡、热量摄入以及减少利尿剂使用有关。